Buy, hold, sell: Endeavour, ResMed, and Westpac shares

Let's see what analysts are saying about these big names.

Key points
  • Endeavour Group is given a hold rating by Morgans due to weaker-than-expected sales and limited near-term upside, despite some positive retail sales indicators.
  • ResMed Inc. is recommended for accumulation as it shows strong revenue and margin growth, driven by high-margin product releases and advancements in AI and digital health.
  • Westpac Banking Corp is a sell according to Morgans, with its shares seen as overvalued despite solid business lending growth, suggesting investors reduce their exposure.

There are a lot of ASX 200 blue chip shares to choose from on the Australian share market.

To narrow things down, let's see what analysts at Morgans are saying about three popular options. Here's what you need to know:

A young man goes over his finances and investment portfolio at home.

Image source: Getty Images

Endeavour Group Ltd (ASX: EDV)

Morgans was disappointed with this drinks giant's first quarter update. It notes that its sales were weaker than expected overall. However, signs of improvement could bode well for the future.

But for now, the broker is sticking with its holding recommendation and trimmed price target of $3.70. Commenting on the Dan Murphy's owner, the broker said:

Our target price decreases to $3.70 (from $4.15) and we maintain our HOLD rating. While there are some encouraging signs in Retail sales heading into the key Christmas trading period, the overall liquor market remains subdued, with consumers continuing to prioritise value. With new CEO Jayne Hrdlicka not commencing her role full-time until January 2026 and an updated strategy not expected until April/May 2026, we see limited upside in EDV in the near term.

ResMed Inc. (ASX: RMD)

Another ASX 200 blue chip share the broker has been looking at is sleep disorder treatment company ResMed.

Morgans was pleased with ResMed's performance during the first quarter. It notes that it continues to deliver strong revenue growth and margin expansion.

In response, the broker has put an accumulate rating and $47.04 price target on its shares. It commented:

We continue to view fundamentals as sound and the company in a strong position to support future earnings growth, with the upper end of FY26 GPM guidance (61-63%) likely achievable given a strong cadence of new high-margin product releases, an expanding US supply chain, along with continued investment in AI and digital health to drive awareness and increase patient diagnosis. FY26-28 earnings change negligibly, with our target price modestly declining to $47.04. ACCUMULATE.

Westpac Banking Corp (ASX: WBC)

Morgans remains bearish on this banking giant following the release of its full year results.

Although it felt the result was solid, it thinks its shares are overvalued at current levels and has retained its sell rating with a slightly improved price target of $31.30. It said:

In the 2H25 result we appreciated the strong business lending growth, resilient asset quality, relatively stable underlying NIM, and regulatory capital strength. Cost investment is being made to deliver long-term revenue and cost gains. With the stock trading around all-time highs but with limited earnings growth over coming years we continue to recommend clients SELL overweight positions.

Motley Fool contributor James Mickleboro has positions in Endeavour Group and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »

colleagues on a lunch break looking at iPhone
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

Woman with her fingers crossed and eyes shut.
Broker Notes

7 ASX 200 shares in the buy zone as optimism returns to the market: experts

Brokers reaffirmed their buy calls on Liontown, Rio Tinto, Xero, and others this week.

Read more »

ASX shares broker ratings represented by three different coloured buttons.
Broker Notes

6 ASX shares upgraded and downgraded by the experts this week

Brokers have changed their ratings and 12-month price targets on Qantas, Codan, and others. 

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Broker Notes

Buy, hold, sell: CSL, NextDC, PLS shares

Mark Elzayed from Vestra Capital explains his ratings on three ASX 200 shares.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Eagers Automotive, REA Group, National Australia Bank: Buy, sell, or hold?

The leader of this pack might surprise.

Read more »

Man sitting in a plane seat works on his laptop.
Broker Notes

Qantas shares were just downgraded but I still rate them as a buy

I think the downgrade was wrong and see value in the airline's shares.

Read more »

Smiling miner.
Broker Notes

4 ASX mining shares with 90% to 155% upside ahead: experts

These ASX mining shares have outstanding price growth potential.

Read more »